TransMedics Group, Inc. (NASDAQ:TMDX) Shares Sold by Kent Lake Capital LLC

Kent Lake Capital LLC lowered its stake in shares of TransMedics Group, Inc. (NASDAQ:TMDXFree Report) by 16.1% in the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 100,000 shares of the company’s stock after selling 19,129 shares during the quarter. TransMedics Group comprises about 2.1% of Kent Lake Capital LLC’s holdings, making the stock its 23rd largest position. Kent Lake Capital LLC owned 0.31% of TransMedics Group worth $5,475,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other institutional investors and hedge funds also recently modified their holdings of the company. Huntington National Bank purchased a new stake in shares of TransMedics Group during the 2nd quarter worth about $30,000. Global Retirement Partners LLC purchased a new position in shares of TransMedics Group during the 3rd quarter valued at approximately $38,000. Cutler Group LLC CA boosted its stake in shares of TransMedics Group by 600.0% during the 3rd quarter. Cutler Group LLC CA now owns 700 shares of the company’s stock valued at $38,000 after buying an additional 600 shares during the last quarter. Ancora Advisors LLC acquired a new stake in shares of TransMedics Group during the 1st quarter valued at approximately $38,000. Finally, First Horizon Advisors Inc. raised its position in shares of TransMedics Group by 45.1% during the 1st quarter. First Horizon Advisors Inc. now owns 544 shares of the company’s stock valued at $41,000 after acquiring an additional 169 shares in the last quarter. Institutional investors and hedge funds own 99.67% of the company’s stock.

Wall Street Analysts Forecast Growth

Several research firms recently issued reports on TMDX. Morgan Stanley upped their price target on TransMedics Group from $75.00 to $95.00 and gave the company an “equal weight” rating in a research report on Wednesday, February 28th. JPMorgan Chase & Co. increased their target price on TransMedics Group from $87.00 to $105.00 and gave the stock an “overweight” rating in a research report on Tuesday, February 27th. Finally, Oppenheimer increased their target price on TransMedics Group from $92.00 to $105.00 and gave the stock an “outperform” rating in a research report on Tuesday, February 27th. One analyst has rated the stock with a hold rating and five have assigned a buy rating to the stock. According to MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $103.75.

Check Out Our Latest Research Report on TMDX

TransMedics Group Price Performance

Shares of NASDAQ:TMDX traded up $4.26 during midday trading on Monday, reaching $86.98. The company had a trading volume of 985,865 shares, compared to its average volume of 625,217. The company has a current ratio of 9.30, a quick ratio of 8.49 and a debt-to-equity ratio of 3.69. TransMedics Group, Inc. has a 1-year low of $36.42 and a 1-year high of $99.63. The company has a fifty day simple moving average of $83.78 and a two-hundred day simple moving average of $68.25.

TransMedics Group (NASDAQ:TMDXGet Free Report) last released its quarterly earnings results on Monday, February 26th. The company reported $0.12 earnings per share for the quarter, beating analysts’ consensus estimates of ($0.10) by $0.22. TransMedics Group had a negative return on equity of 2.35% and a negative net margin of 10.36%. The business had revenue of $81.20 million during the quarter, compared to analyst estimates of $68.49 million. During the same quarter last year, the company posted ($0.21) EPS. TransMedics Group’s revenue for the quarter was up 158.6% on a year-over-year basis. Research analysts forecast that TransMedics Group, Inc. will post -0.17 earnings per share for the current year.

Insider Buying and Selling at TransMedics Group

In other TransMedics Group news, insider Tamer I. Khayal sold 2,330 shares of TransMedics Group stock in a transaction dated Tuesday, January 23rd. The stock was sold at an average price of $90.09, for a total transaction of $209,909.70. Following the transaction, the insider now owns 14,375 shares of the company’s stock, valued at approximately $1,295,043.75. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. In other TransMedics Group news, CFO Stephen Gordon sold 15,000 shares of TransMedics Group stock in a transaction dated Tuesday, January 2nd. The stock was sold at an average price of $77.07, for a total transaction of $1,156,050.00. Following the transaction, the chief financial officer now owns 13,075 shares of the company’s stock, valued at approximately $1,007,690.25. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, insider Tamer I. Khayal sold 2,330 shares of TransMedics Group stock in a transaction dated Tuesday, January 23rd. The shares were sold at an average price of $90.09, for a total value of $209,909.70. Following the transaction, the insider now directly owns 14,375 shares in the company, valued at approximately $1,295,043.75. The disclosure for this sale can be found here. Insiders have sold a total of 55,371 shares of company stock valued at $4,538,240 in the last 90 days. 6.70% of the stock is currently owned by corporate insiders.

TransMedics Group Company Profile

(Free Report)

TransMedics Group, Inc, a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body.

Featured Stories

Want to see what other hedge funds are holding TMDX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for TransMedics Group, Inc. (NASDAQ:TMDXFree Report).

Institutional Ownership by Quarter for TransMedics Group (NASDAQ:TMDX)

Receive News & Ratings for TransMedics Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TransMedics Group and related companies with MarketBeat.com's FREE daily email newsletter.